Whalegun
Home

Ultragenyx Pharmaceutical RARE paid Forbes-Tate $50K for lobbying in Q4 2022 · Health Issues

Trade details

Type
Lobbying report
Amount
$50,000
Quarter
Q4 2022
Stock
Ultragenyx Pharmaceutical RARE
Client
Ultragenyx Pharmaceutical
Reported
23/01/17

$50K on lobbying in 2022

What else happened in Ultragenyx Pharmaceutical around then

Filed or reported within 30 days of the trade day · 22/12/01~23/01/30

Ultragenyx Pharmaceutical's other lobbying reports